Clinical Trial Update: Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial examining Lu-177-PSMA-617 in patients with high-risk localized prostate cancer undergoing radical prostatectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lu-177-PSMA-617 (Lutetium-177-PSMA-617)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING